Sentinel lymph node biopsy utilization and positivity in veterans with cutaneous melanoma: A comparative analysis of the VA Cancer Registry and the SEER Program - 12/06/26
Doi : 10.1016/j.jaad.2026.03.124
Daniel Y. Kim, BS a, b, Susan M. Swetter, MD c, d, Linden Huhmann, MS, PhD e, Jacqueline M. Ferguson, PhD f, Kimberly Breglio, MD, DPhil g, Allyson C. Spence, MD, PhD h, Lee Wheless, MD, PhD i, j, k, Mary T. Brophy, MD l, m, Nhan V. Do, MD l, m, Nathanael Fillmore, PhD a, e, m, n, Rebecca I. Hartman, MD, MPH a, b, o, ⁎ 
a Harvard Medical School, Boston, Massachusetts
b Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts
c Department of Dermatology, Stanford University Medical Center, Palo Alto, California
d Dermatology Service, Veterans Affairs Palo Alto Health Care System, Palo Alto, California
e Massachusetts Veterans Epidemiology Research and Information Center, Veterans Affairs Boston Healthcare System, Boston, Massachusetts
f Center for Innovation to Implementation, Veterans Affairs Palo Alto Health Care System, Menlo Park, California
g Department of Dermatology, University of Michigan, Ann Arbor, Michigan
h Department of Medical Oncology, Stanford University Medical Center, Palo Alto, California
i Department of Dermatology, Vanderbilt University Medical Center, Nashville, Tennessee
j Division of Epidemiology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee
k Tennessee Valley Healthcare System VA Medical Center, Nashville, Tennessee
l Boston University School of Medicine, Boston, Massachusetts
m Department of Medicine, Veterans Affairs Boston Healthcare System, Boston, Massachusetts
n Dana Farber Cancer Institute, Boston, Massachusetts
o Dermatology Section, VA Integrated Service Network 1 (VISN-1), Jamaica Plain, Massachusetts
∗ Correspondence to: Rebecca I. Hartman, MD, MPH, Department of Dermatology, Brigham and Women's Hospital, 221 Longwood Ave, Boston, Massachusetts 02115 Department of Dermatology Brigham and Women's Hospital 221 Longwood Ave Boston Massachusetts 02115
Sous presse. Épreuves corrigées par l'auteur.
Disponible en ligne depuis le Friday 12 June 2026
Key words : Breslow, cutaneous, dermatology, melanoma, oncology, SEER, Surveillance, Epidemiology, and End Results program, T2, T3, T4, thickness, VA, veteran, Veterans Affairs
| Drs Fillmore and Hartman contributed equally. |
|
| Funding sources: Drs Hartman and Fillmore are supported by the Department of Defense under award number W81XWH2110819 . Dr Hartman is also supported by the Department of Veterans Affairs under award number VA CSR & D IK2 CX-002531. Dr Wheless is supported by VA CSR & D award CX-002452. This material is the result of work supported with resources and the use of facilities at the Veterans Affairs Palo Alto Health Care System in Palo Alto, California and the Veterans Affairs Boston Health Care in Boston, Massachusetts. |
|
| Patient consent: Not applicable. |
|
| IRB approval status: Approved by the VA Boston Healthcare System (Protocol #3209). |
© 2026
Publié par Elsevier Masson SAS.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?